Nikkomycin Z treatment of early coccidioidal pneumonia: Phase II clinical trial
尼可霉素 Z 治疗早期球孢子菌肺炎:II 期临床试验
基本信息
- 批准号:7925199
- 负责人:
- 金额:$ 299.98万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2010
- 资助国家:美国
- 起止时间:2010-05-08 至 2013-09-30
- 项目状态:已结题
- 来源:
- 关键词:Acquired Immunodeficiency SyndromeAffectAfricanAfrican AmericanAnimalsAntifungal AgentsArizonaBacteriaBioterrorismBusinessesCell WallChitinChitin SynthaseChronicChronic DiseaseClinicalClinical ManagementClinical TrialsCoccidioidomycosisDevelopmentDoseDrug ApprovalDrug Delivery SystemsDrug FormulationsDrug usageEarly treatmentElderlyEnrollmentEnzyme GeneFeverFilipinoFutureGene DeletionGeneticGrowthHumanHuman GenomeImmunocompromised HostInfectionInvestmentsLifeMammalsMedicalMethodsMilitary PersonnelModificationMorbidity - disease rateMycosesNative AmericansOrgan TransplantationOrphanOrphan DiseasePathway interactionsPersonsPharmaceutical PreparationsPharmacologic SubstancePhasePhase I Clinical TrialsPhase II Clinical TrialsPlacebosPlayPneumoniaPregnant WomenPriceProcessResearchRiskRoleSafetySolutionsSourceSouthwestern United StatesStreptomycesTestingTherapeuticTimeToxic effectTrainingUniversitiesWorkbasecapsulecommercializationcostefficacy trialfollow-upfungusimmunosuppressedinhibitor/antagonistinnovationmanufacturing processmanufacturing scale-upmedical attentionnikkomycinnikkomycin Xphase 1 studyphase 2 studypreventprocess optimizationpublic health relevanceresponsescale up
项目摘要
DESCRIPTION (provided by applicant): Coccidioidomycosis (Valley Fever) is an orphan fungal infection endemic to the US southwest, for which approximately 50,000 persons seek medical attention each year. It disproportionately affects Native Americans who live there, and severe infections are much more likely in African-Americans and Filipinos. Also at particular risk are immunosuppressed patients such as those with AIDS or recipients of organ transplants, pregnant women, the elderly and military personnel who train in the endemic desert regions. The fungi that cause Valley Fever are potential agents of bioterrorism. Currently available medical treatments are only partially effective and do not cure infections. Nikkomycin Z is a first-in-class antifungal drug which inhibits fungal cell wall development. The drug's targets, chitin synthases, play important roles to support fungal growth but chitin is not found in mammals and the genes for enzymes that make chitin do not exist in the human genome. Because of this difference, effects of nikkomycin Z should be very selective for its antifungal effect and potentially very safe if administered to humans as a medical therapeutic. In experimental animal infections, nikkomycin Z has been shown to be curative. In ongoing multi-dose human safety Phase I trials nikkomycin Z has thus far showed little or no toxicity. Our hypothesis is that early treatment of coccidioidal infections will safely eradicate infection, thereby preventing serious complications and avoiding the chronic morbidity that now requires many years or even life-long treatment with conventional medications. We will need to continue clinical trials to test this hypothesis in humans. If commercialization of nikkomycin Z is successful, the Valley Fever Solutions business plan projects $250 million annual revenue within 5 years of NDA approval. In order to attract the needed pharmaceutical investment to do this, we propose to reduce the development risk for a partner by 1) creating a less expensive manufacturing process and 2) using the drug produced by the new process in an initial efficacy trial in humans ("Phase II" in the FDA drug approval sequence). Our new manufacturing process is based upon a strain of the drug-producing bacteria that we have genetically modified. The modifications have interrupted the synthesis of an inactive metabolite (nikkomycin X) that made the previous purification of nikkomycin Z very inefficient, and expensive. By eliminating nikkomycin X, fewer steps will be needed and more of the produced nikkomycin Z will be recovered in the purification process, thus reducing the overall cost of goods. The clinical trial that we propose for our second aim will compare therapeutic responses in groups of subjects receiving one of three different dose/durations of nikkomycin Z or placebo treatments. This should provide the basis for future pivotal trials.
PUBLIC HEALTH RELEVANCE: This project will further the development of a new, potentially curative drug, nikkomycin Z, to treat the fungal infection, Valley Fever (coccidioidomycosis). A Valley Fever cure would be particularly valuable to groups disproportionately affected by infection such as African Americans, Filipinos, Native American peoples, persons with AIDS or other immunosuppressing conditions, the military, and the elderly. We propose to develop the methods to make this drug at an affordable price and to study the newly made nikkomycin Z in humans to identify and select effective doses for future studies.
描述(由申请人提供):球孢子菌病(谷热)是美国西南部流行的一种孤儿真菌感染,每年约有 50,000 人寻求医疗护理。它对居住在那里的美洲原住民造成了不成比例的影响,非洲裔美国人和菲律宾人更容易受到严重感染。同样面临特别风险的是免疫抑制患者,例如艾滋病患者或器官移植接受者、孕妇、老年人和在流行沙漠地区训练的军人。引起山谷热的真菌是生物恐怖主义的潜在媒介。目前可用的医疗方法仅部分有效,并且不能治愈感染。 Nikkomycin Z 是一种一流的抗真菌药物,可抑制真菌细胞壁的发育。该药物的靶标几丁质合酶在支持真菌生长方面发挥着重要作用,但哺乳动物中没有发现几丁质,人类基因组中也不存在制造几丁质的酶基因。由于这种差异,尼可霉素 Z 的抗真菌作用应该具有很强的选择性,并且如果作为医学治疗剂用于人体,可能非常安全。在实验动物感染中,尼可霉素 Z 已被证明具有治疗作用。在正在进行的多剂量人体安全 I 期试验中,尼可霉素 Z 迄今为止显示出很少或没有毒性。我们的假设是,球孢子菌感染的早期治疗将安全地根除感染,从而预防严重的并发症并避免目前需要使用常规药物进行多年甚至终生治疗的慢性发病率。我们需要继续进行临床试验,以在人体中检验这一假设。如果 Nikkomycin Z 的商业化成功,Valley Fever Solutions 业务计划预计在 NDA 批准后 5 年内年收入将达到 2.5 亿美元。为了吸引实现这一目标所需的制药投资,我们建议通过以下方式降低合作伙伴的开发风险:1)创建更便宜的制造工艺;2)在人体初步疗效试验中使用新工艺生产的药物(FDA 药物批准序列中的“第二阶段”)。我们的新制造工艺基于我们经过基因改造的产药细菌菌株。这些修饰中断了无活性代谢物(尼可霉素 X)的合成,使得之前尼可霉素 Z 的纯化效率非常低且昂贵。通过消除尼可霉素 X,将需要更少的步骤,并且在纯化过程中将回收更多产生的尼可霉素 Z,从而降低商品的总体成本。我们为第二个目标提出的临床试验将比较接受三种不同剂量/持续时间的尼可霉素 Z 或安慰剂治疗之一的受试者组的治疗反应。这应该为未来的关键试验提供基础。
公共健康相关性:该项目将进一步开发一种新的、潜在的治疗药物尼可霉素 Z,用于治疗真菌感染谷热(球孢子菌病)。山谷热的治疗方法对于受感染影响较大的群体尤其有价值,例如非裔美国人、菲律宾人、美洲原住民、艾滋病患者或其他免疫抑制疾病患者、军人和老年人。我们建议开发方法以可承受的价格生产这种药物,并在人体中研究新制造的尼可霉素 Z,以确定和选择未来研究的有效剂量。
项目成果
期刊论文数量(1)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
A practical and scalable manufacturing process for an anti-fungal agent, Nikkomycin Z.
- DOI:10.1021/op3003294
- 发表时间:2013-02-15
- 期刊:
- 影响因子:3.4
- 作者:Stenland CJ;Lis LG;Schendel FJ;Hahn NJ;Smart MA;Miller AL;von Keitz MG;Gurvich VJ
- 通讯作者:Gurvich VJ
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
JOHN N GALGIANI其他文献
JOHN N GALGIANI的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('JOHN N GALGIANI', 18)}}的其他基金
Immuno-Genetic Basis for Human Disseminated Coccidioidomycosis
人类播散性球孢子菌病的免疫遗传学基础
- 批准号:
9457306 - 财政年份:2017
- 资助金额:
$ 299.98万 - 项目类别:
Immuno-Genetic Basis for Human Disseminated Coccidioidomycosis
人类播散性球孢子菌病的免疫遗传学基础
- 批准号:
9884535 - 财政年份:2017
- 资助金额:
$ 299.98万 - 项目类别:
An Avirulent Arthroconidial Vaccine Candidate to Prevent Human Coccidioidomycosis
一种预防人类球孢子菌病的无毒节分孢子疫苗候选物
- 批准号:
9360833 - 财政年份:2017
- 资助金额:
$ 299.98万 - 项目类别:
Immuno-Genetic Basis for Human Disseminated Coccidioidomycosis
人类播散性球孢子菌病的免疫遗传学基础
- 批准号:
9258955 - 财政年份:2017
- 资助金额:
$ 299.98万 - 项目类别:
Coccidioides Proteins as Vaccine Antigens and Diagnostic Biosignatures
球孢子菌蛋白作为疫苗抗原和诊断生物特征
- 批准号:
8260265 - 财政年份:2011
- 资助金额:
$ 299.98万 - 项目类别:
Coccidioides Proteins as Vaccine Antigens and Diagnostic Biosignatures
球孢子菌蛋白作为疫苗抗原和诊断生物特征
- 批准号:
7675204 - 财政年份:2009
- 资助金额:
$ 299.98万 - 项目类别:
Experimental Pharmacology and Chemical Studies of Nikkomycin Z
尼可霉素 Z 的实验药理学和化学研究
- 批准号:
7736460 - 财政年份:2008
- 资助金额:
$ 299.98万 - 项目类别:
Experimental Pharmacology and Chemical Studies of Nikkomycin Z
尼可霉素 Z 的实验药理学和化学研究
- 批准号:
7406159 - 财政年份:2008
- 资助金额:
$ 299.98万 - 项目类别:
Nikkomycin Z Treatment for Coccidioidomycosis
尼可霉素 Z 治疗球孢子菌病
- 批准号:
7187295 - 财政年份:2006
- 资助金额:
$ 299.98万 - 项目类别:
相似海外基金
RII Track-4:NSF: From the Ground Up to the Air Above Coastal Dunes: How Groundwater and Evaporation Affect the Mechanism of Wind Erosion
RII Track-4:NSF:从地面到沿海沙丘上方的空气:地下水和蒸发如何影响风蚀机制
- 批准号:
2327346 - 财政年份:2024
- 资助金额:
$ 299.98万 - 项目类别:
Standard Grant
BRC-BIO: Establishing Astrangia poculata as a study system to understand how multi-partner symbiotic interactions affect pathogen response in cnidarians
BRC-BIO:建立 Astrangia poculata 作为研究系统,以了解多伙伴共生相互作用如何影响刺胞动物的病原体反应
- 批准号:
2312555 - 财政年份:2024
- 资助金额:
$ 299.98万 - 项目类别:
Standard Grant
How Does Particle Material Properties Insoluble and Partially Soluble Affect Sensory Perception Of Fat based Products
不溶性和部分可溶的颗粒材料特性如何影响脂肪基产品的感官知觉
- 批准号:
BB/Z514391/1 - 财政年份:2024
- 资助金额:
$ 299.98万 - 项目类别:
Training Grant
Graduating in Austerity: Do Welfare Cuts Affect the Career Path of University Students?
紧缩毕业:福利削减会影响大学生的职业道路吗?
- 批准号:
ES/Z502595/1 - 财政年份:2024
- 资助金额:
$ 299.98万 - 项目类别:
Fellowship
感性個人差指標 Affect-X の構築とビスポークAIサービスの基盤確立
建立个人敏感度指数 Affect-X 并为定制人工智能服务奠定基础
- 批准号:
23K24936 - 财政年份:2024
- 资助金额:
$ 299.98万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Insecure lives and the policy disconnect: How multiple insecurities affect Levelling Up and what joined-up policy can do to help
不安全的生活和政策脱节:多种不安全因素如何影响升级以及联合政策可以提供哪些帮助
- 批准号:
ES/Z000149/1 - 财政年份:2024
- 资助金额:
$ 299.98万 - 项目类别:
Research Grant
How does metal binding affect the function of proteins targeted by a devastating pathogen of cereal crops?
金属结合如何影响谷类作物毁灭性病原体靶向的蛋白质的功能?
- 批准号:
2901648 - 财政年份:2024
- 资助金额:
$ 299.98万 - 项目类别:
Studentship
ERI: Developing a Trust-supporting Design Framework with Affect for Human-AI Collaboration
ERI:开发一个支持信任的设计框架,影响人类与人工智能的协作
- 批准号:
2301846 - 财政年份:2023
- 资助金额:
$ 299.98万 - 项目类别:
Standard Grant
Investigating how double-negative T cells affect anti-leukemic and GvHD-inducing activities of conventional T cells
研究双阴性 T 细胞如何影响传统 T 细胞的抗白血病和 GvHD 诱导活性
- 批准号:
488039 - 财政年份:2023
- 资助金额:
$ 299.98万 - 项目类别:
Operating Grants
How motor impairments due to neurodegenerative diseases affect masticatory movements
神经退行性疾病引起的运动障碍如何影响咀嚼运动
- 批准号:
23K16076 - 财政年份:2023
- 资助金额:
$ 299.98万 - 项目类别:
Grant-in-Aid for Early-Career Scientists